How does 7595's PS Ratio compare to its peers?

7595 is good value based on its Price-To-Sales Ratio (5.4x) compared to the peer average (6.1x).

How does 7595's PS Ratio compare vs other companies in the TW Biotechs Industry?

7595 is good value based on its Price-To-Sales Ratio (5.4x) compared to the TW Biotechs industry average (24.3x).

What is 7595's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 7595's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of 7595 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 7595's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

7595 Stock Overview

Designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. More details

7595 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings have declined by 34.9% per year over past 5 years

Does not have meaningful revenue (NT$127M)

Does not have a meaningful market cap (NT$689M)

My Notes

Capture your thoughts, links and company narrative

Pharmigene, Inc. Competitors

Bioray Biotech

TPEX:7561

NT$635.4m

Vectorite Biomedical

TPEX:4170

NT$636.9m

Genomics BioSci & Tech.Ltd

TPEX:4195

NT$1.4b

Lukas Biomedical

TPEX:6814

NT$1.3b

Price History & Performance

Summary of share price highs, lows and changes for Pharmigene
Historical stock prices
Current Share Price	NT$13.65
52 Week High	NT$21.10
52 Week Low	NT$12.50
Beta	0.12
1 Month Change	-2.50%
3 Month Change	-18.26%
1 Year Change	-34.06%
3 Year Change	-37.10%
5 Year Change	n/a
Change since IPO	-45.18%

Recent updates

Shareholder Returns

	7595	TW Biotechs	TW Market
7D	1.1%	4.5%	3.2%
1Y	-34.1%	2.6%	27.5%

Return vs Industry: 7595 underperformed the TW Biotechs industry which returned 3.2% over the past year.

Return vs Market: 7595 underperformed the TW Market which returned 27.5% over the past year.

Price Volatility

Is 7595's price volatile compared to industry and market?
7595 volatility
7595 Average Weekly Movement	5.8%
Biotechs Industry Average Movement	4.5%
Market Average Movement	4.4%
10% most volatile stocks in TW Market	7.7%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 7595 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 7595's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1994	n/a	Sophia Zhan	pharmigene.com.tw

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test, and functional medicine test services.

Pharmigene, Inc. Fundamentals Summary

How do Pharmigene's earnings and revenue compare to its market cap?
7595 fundamental statistics
Market cap	NT$688.85m
Earnings (TTM)	-NT$92.66m
Revenue (TTM)	NT$126.99m

5.4x

P/S Ratio

-7.4x

P/E Ratio

Is 7595 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7595 income statement (TTM)
Revenue	NT$126.99m
Cost of Revenue	NT$85.00m
Gross Profit	NT$41.99m
Other Expenses	NT$134.65m
Earnings	-NT$92.66m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.84
Gross Margin	33.07%
Net Profit Margin	-72.97%
Debt/Equity Ratio	152.2%

How did 7595 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 09:41
End of Day Share Price	2024/12/27 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharmigene, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution